Copyright Reports & Markets. All rights reserved.

Dynamics in Post-pandemic Global Influenzavirus B Infection Drug Industry: Supply and Demand, Markets and Prices 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Influenzavirus B Infection Drug Market Status and Forecast (2016-2027)
      • 1.3.2 Global Influenzavirus B Infection Drug Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Influenzavirus B Infection Drug Supply by Company

    • 2.1 Global Influenzavirus B Infection Drug Sales Volume by Company
    • 2.2 Global Influenzavirus B Infection Drug Sales Value by Company
    • 2.3 Global Influenzavirus B Infection Drug Price by Company
    • 2.4 Influenzavirus B Infection Drug Production Location and Sales Area of Main Manufacturers
    • 2.5 Trend of Concentration Rate

    3 Global and Regional Influenzavirus B Infection Drug Market Status by Category

    • 3.1 Influenzavirus B Infection Drug Category Introduction
      • 3.1.1 APP-309
      • 3.1.2 CF-403
      • 3.1.3 GC-3106A
      • 3.1.4 KIN-1400
      • 3.1.5 Others
    • 3.2 Global Influenzavirus B Infection Drug Market by Category
      • 3.2.1 Global Influenzavirus B Infection Drug Sales Volume by Category (2016-2021)
      • 3.2.2 Global Influenzavirus B Infection Drug Sales Value by Category (2016-2021)
      • 3.2.3 Global Influenzavirus B Infection Drug Price by Category (2016-2021)
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Influenzavirus B Infection Drug Market Status by End User/Segment

    • 4.1 Influenzavirus B Infection Drug Segment by End User/Segment
      • 4.1.1 Clinic
      • 4.1.2 Hospital
      • 4.1.3 Others
    • 4.2 Global Influenzavirus B Infection Drug Market by End User/Segment
      • 4.2.1 Global Influenzavirus B Infection Drug Sales Volume by End User/Segment (2016-2021)
      • 4.2.2 Global Influenzavirus B Infection Drug Sales Value by End User/Segment (2016-2021)
      • 4.2.3 Global Influenzavirus B Infection Drug Price by End User/Segment (2016-2021)
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Influenzavirus B Infection Drug Market Status by Region

    • 5.1 Global Influenzavirus B Infection Drug Market by Region
      • 5.1.1 Global Influenzavirus B Infection Drug Sales Volume by Region
      • 5.1.2 Global Influenzavirus B Infection Drug Sales Value by Region
    • 5.2 North America Influenzavirus B Infection Drug Market Status
    • 5.3 Europe Influenzavirus B Infection Drug Market Status
    • 5.4 Asia Pacific Influenzavirus B Infection Drug Market Status
    • 5.5 Central & South America Influenzavirus B Infection Drug Market Status
    • 5.6 Middle East & Africa Influenzavirus B Infection Drug Market Status

    6 North America Influenzavirus B Infection Drug Market Status

    • 6.1 North America Influenzavirus B Infection Drug Market by Country
      • 6.1.1 North America Influenzavirus B Infection Drug Sales Volume by Country (2016-2021)
      • 6.1.2 North America Influenzavirus B Infection Drug Sales Value by Country (2016-2021)
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Influenzavirus B Infection Drug Market Status

    • 7.1 Europe Influenzavirus B Infection Drug Market by Country
      • 7.1.1 Europe Influenzavirus B Infection Drug Sales Volume by Country (2016-2021)
      • 7.1.2 Europe Influenzavirus B Infection Drug Sales Value by Country (2016-2021)
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Influenzavirus B Infection Drug Market Status

    • 8.1 Asia Pacific Influenzavirus B Infection Drug Market by Country
      • 8.1.1 Asia Pacific Influenzavirus B Infection Drug Sales Volume by Country (2016-2021)
      • 8.1.2 Asia Pacific Influenzavirus B Infection Drug Sales Value by Country (2016-2021)
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Influenzavirus B Infection Drug Market Status

    • 9.1 Central & South America Influenzavirus B Infection Drug Market by Country
      • 9.1.1 Central & South America Influenzavirus B Infection Drug Sales Volume by Country (2016-2021)
      • 9.1.2 Central & South America Influenzavirus B Infection Drug Sales Value by Country (2016-2021)
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Influenzavirus B Infection Drug Market Status

    • 10.1 Middle East & Africa Influenzavirus B Infection Drug Market by Country
      • 10.1.1 Middle East & Africa Influenzavirus B Infection Drug Sales Volume by Country (2016-2021)
      • 10.1.2 Middle East & Africa Influenzavirus B Infection Drug Sales Value by Country (2016-2021)
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Supply Chain and Manufacturing Cost Analysis

    • 11.1 Supply Chain Analysis
    • 11.2 Production Process Chart Analysis
    • 11.3 Raw Materials and Key Suppliers Analysis
      • 11.3.1 Raw Materials Introduction
      • 11.3.2 Raw Materials Key Suppliers List
    • 11.4 Influenzavirus B Infection Drug Manufacturing Cost Analysis
    • 11.5 Influenzavirus B Infection Drug Sales Channel and Distributors Analysis
      • 11.5.1 Influenzavirus B Infection Drug Sales Channel
      • 11.5.2 Influenzavirus B Infection Drug Distributors
    • 11.6 Influenzavirus B Infection Drug Downstream Major Buyers

    12 Global Influenzavirus B Infection Drug Market Forecast by Category and by End User/Segment

    • 12.1 Global Influenzavirus B Infection Drug Sales Volume and Sales Value Forecast (2022-2027)
    • 12.2 Global Influenzavirus B Infection Drug Forecast by Category
      • 12.2.1 Global Influenzavirus B Infection Drug Sales Volume Forecast by Category
      • 12.2.2 Global Influenzavirus B Infection Drug Sales Value Forecast by Category
      • 12.2.3 Global Influenzavirus B Infection Drug Price Forecast by Category
    • 12.3 Global Influenzavirus B Infection Drug Forecast by End User/Segment
      • 12.3.1 Global Influenzavirus B Infection Drug Sales Volume Forecast by End User/Segment
      • 12.3.2 Global Influenzavirus B Infection Drug Sales Value Forecast by End User/Segment
      • 12.3.3 Global Influenzavirus B Infection Drug Price Forecast by End User/Segment

    13 Global Influenzavirus B Infection Drug Market Forecast by Region/Country

    • 13.1 Global Influenzavirus B Infection Drug Market Forecast by Region (2022-2027)
      • 13.1.1 Global Influenzavirus B Infection Drug Sales Volume Forecast by Region (2022-2027)
      • 13.1.2 Global Influenzavirus B Infection Drug Sales Value Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 Vectura Group Plc
      • 14.1.1 Company Information
      • 14.1.2 Influenzavirus B Infection Drug Product Introduction
      • 14.1.3 Vectura Group Plc Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Vaxart Inc
      • 14.2.1 Company Information
      • 14.2.2 Influenzavirus B Infection Drug Product Introduction
      • 14.2.3 Vaxart Inc Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 TSRL Inc
      • 14.3.1 Company Information
      • 14.3.2 Influenzavirus B Infection Drug Product Introduction
      • 14.3.3 TSRL Inc Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 SK Chemicals Co Ltd
      • 14.4.1 Company Information
      • 14.4.2 Influenzavirus B Infection Drug Product Introduction
      • 14.4.3 SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Shionogi & Co Ltd
      • 14.5.1 Company Information
      • 14.5.2 Influenzavirus B Infection Drug Product Introduction
      • 14.5.3 Shionogi & Co Ltd Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Sanofi
      • 14.6.1 Company Information
      • 14.6.2 Influenzavirus B Infection Drug Product Introduction
      • 14.6.3 Sanofi Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 Sanofi Pasteur SA
      • 14.7.1 Company Information
      • 14.7.2 Influenzavirus B Infection Drug Product Introduction
      • 14.7.3 Sanofi Pasteur SA Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 Romark Laboratories LC
      • 14.8.1 Company Information
      • 14.8.2 Influenzavirus B Infection Drug Product Introduction
      • 14.8.3 Romark Laboratories LC Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.8.4 SWOT Analysis
    • 14.9 Park Active Molecules
      • 14.9.1 Company Information
      • 14.9.2 Influenzavirus B Infection Drug Product Introduction
      • 14.9.3 Park Active Molecules Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.9.4 SWOT Analysis
    • 14.10 Novavax Inc
      • 14.10.1 Company Information
      • 14.10.2 Influenzavirus B Infection Drug Product Introduction
      • 14.10.3 Novavax Inc Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.10.4 SWOT Analysis
    • 14.11 Mucosis BV
    • 14.12 MedImmune LLC
    • 14.13 Medicago Inc
    • 14.14 Kineta Inc
    • 14.15 Inovio Pharmaceuticals Inc
    • 14.16 Green Cross Corp
    • 14.17 GlaxoSmithKline Plc
    • 14.18 Fujifilm Holdings Corporation
    • 14.19 Daiichi Sankyo Company Ltd
    • 14.20 ContraFect Corp
    • 14.21 Cadila Healthcare Ltd
    • 14.22 BioCryst Pharmaceuticals Inc
    • 14.23 Aphios Corp
    • 14.24 Amarillo Biosciences Inc
    • 14.25 Altravax Inc
    • 14.26 Adimmune Corp
    • 14.27 AbbVie Inc

    15 Conclusion

      16 Methodology

      Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Influenzavirus B Infection Drug market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. From industry perspective this report analyses supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Influenzavirus B Infection Drug market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

      Segmented by Category
      APP-309
      CF-403
      GC-3106A
      KIN-1400
      Others

      Segmented by End User/Segment
      Clinic
      Hospital
      Others

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      Vectura Group Plc
      Vaxart Inc
      TSRL Inc
      SK Chemicals Co Ltd
      Shionogi & Co Ltd
      Sanofi
      Sanofi Pasteur SA
      Romark Laboratories LC
      Park Active Molecules
      Novavax Inc
      Mucosis BV
      MedImmune LLC
      Medicago Inc
      Kineta Inc
      Inovio Pharmaceuticals Inc
      Green Cross Corp
      GlaxoSmithKline Plc
      Fujifilm Holdings Corporation
      Daiichi Sankyo Company Ltd
      ContraFect Corp
      Cadila Healthcare Ltd
      BioCryst Pharmaceuticals Inc
      Aphios Corp
      Amarillo Biosciences Inc
      Altravax Inc
      Adimmune Corp
      AbbVie Inc
      Buy now